deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03782415

Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma

Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma

Sponsor: MediciNova

Conditions GBM Glioblastoma Newly Diagnosed Glioblastoma Recurrent Glioblastoma
Interventions MN-166 Temozolomide
Updated 15 times since 2019 Last updated: May 16, 2025 Started: Dec 29, 2018 Primary completion: Aug 7, 2023 Completion: Aug 7, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates GBM and Glioblastoma and is currently completed. MediciNova leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

15 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Oct 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Mar 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MediciNova
Data source: MediciNova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations